Gyre Therapeutics gets IND okay from China’s NMPA to evaluate F230 for PAH

Gyre Therapeutics announced that the Center for Drug Evaluation CDE of China’s National Medical Products Administration NMPA has approved Gyre Pharmaceuticals’ ( Investigational New Drug or IND, application for F230 tablets, a selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension or PAH. F230 was originally licensed from Eisai through Gyre’s indirect majority stockholder, GNI Group Ltd. “PAH is a rare disease and a progressive, life-threatening disorder that represents a significant unmet need with no known cure,” said Han Ying, Ph.D., Chief Executive Officer of Gyre. “Through Gyre Pharmaceuticals, we are committed to advancing F230 through clinical development with the ultimate goal of improving patient outcomes and enhancing the quality of life for those affected by this devastating condition.”